CURRENT STATUS
CD19 CAR-T cell therapy is producing something unprecedented: drug-free remission in refractory lupus, scleroderma, and myositis. The CASTLE and related trials show patients coming off all immunosuppression. Targeted biologics and JAK inhibitors already transform rheumatoid arthritis, and AI is decoding which autoimmune pathway drives each patient.
KEY BREAKTHROUGHS
CD19 CAR-T (CASTLE trial) β drug-free remission in refractory lupus, scleroderma, and myositis; patients off all immunosuppression
Anifrolumab (Saphnelo) β first type-I interferon receptor blocker approved for systemic lupus
JAK inhibitors (upadacitinib, others) delivering low-disease-activity remission in rheumatoid arthritis
Bispecific T-cell engagers (e.g., teclistamab-class) entering autoimmune trials as an off-the-shelf alternative to CAR-T
AI-COMPRESSED PIPELINE
AI TOOLS ACCELERATING CURES
KEY ORGANIZATIONS
KEY CLINICAL TRIALS
CD19 CAR-T for Refractory Lupus, Scleroderma & Myositis (CASTLE-class)
ViewKyverna / Cabaletta / academic (multi-program)
A single infusion of CD19-targeting CAR-T cells deeply depletes autoreactive B cells, aiming to "reboot" the immune system. Early basket studies report drug-free remission with no high-grade cytokine release syndrome.
Bispecific T-cell Engagers in Autoimmune Disease
ViewMultiple sponsors
Off-the-shelf antibodies that redirect T cells to destroy autoreactive B cells without manufacturing patient-specific cells β aiming to make the CAR-T "immune reset" faster and more scalable.
TIMELINE ESTIMATE
RA low-disease-activity remission: available now. CAR-T drug-free remission for severe lupus/scleroderma: 2β5 years to broader access. Broad autoimmune cure: 5β10 years.